Health Economists

Canadian public HTA and reimbursement review body supporting evidence appraisal for access decisions.

U.S.-based health economics research center (Tufts Medical Center) that curates the CEA Registry and supports cost-effectiveness and value-assessment research used in market-access decision-making.

Germany’s highest joint self-governing HTA decision body for coverage and evidence appraisal, including esketamine/Spravato dossiers.

Global HEOR professional society with major U.S. footprint and an evidence dissemination platform that includes psychedelic-adjacent esketamine budget-impact analyses.

U.S. value assessment organization that publishes comparative effectiveness and cost-effectiveness reports used by payers and policymakers, including assessments relevant to esketamine.

MAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.

UK HTA body issuing evidence and cost-effectiveness recommendations that influence medicine access.

State-level Oregon pharmacy and therapeutics decision body supporting evidence-driven formulary and utilization policy.

Australia’s HTA and reimbursement advisory body for PBS listing decisions, including esketamine (Spravato) assessment materials.

Scotland’s public HTA body issuing medicine acceptance guidance, including esketamine (Spravato) advice.

Washington State HTA program conducting evidence review that informs state coverage and utilization policy.